High Pointe Capital Management’s AbbVie ABBV Stock Holding History

High Pointe Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.68M	Sell	22,712 -1,670	-7%	-$243K	2.64%	3
2021 Q4	$3.3M	Buy	24,382 +2,892	+13%	+$342K	2.2%	6
2021 Q3	$2.32M	Hold	21,490	–	–	1.83%	16
2021 Q2	$2.42M	Sell	21,490 -480	-2%	-$54.1K	1.91%	11
2021 Q1	$2.38M	Buy	+21,970	New	+$2.35M	2.09%	13
2016 Q3	–	Sell	-8,020	Closed	-$497K	–	76
2016 Q2	$497K	Hold	8,020	–	–	0.76%	51
2016 Q1	$458K	Sell	8,020 -42,090	-84%	-$2.35M	0.66%	48
2015 Q4	$2.97M	Sell	50,110 -11,460	-19%	-$660K	1.46%	12
2015 Q3	$3.35M	Buy	61,570 +660	+1%	+$43K	1.57%	10
2015 Q2	$4.09M	Sell	60,910 -1,110	-2%	-$72.5K	1.46%	7
2015 Q1	$3.63M	Buy	62,020 +23,920	+63%	+$1.45M	1.3%	11
2014 Q4	$2.49M	Hold	38,100	–	–	1.1%	16
2014 Q3	$2.2M	Sell	38,100 -27,400	-42%	-$1.52M	0.95%	30
2014 Q2	$3.7M	Buy	65,500 +22,590	+53%	+$1.19M	1.35%	6
2014 Q1	$2.21M	Buy	42,910 +560	+1%	+$28.3K	0.85%	49
2013 Q4	$2.24M	Sell	42,350 -9,400	-18%	-$462K	0.88%	41
2013 Q3	$2.31M	Hold	51,750	–	–	0.93%	38
2013 Q2	$2.14M	Buy	+51,750	New	+$2.26M	0.94%	33

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

High Pointe Capital Management's ABBV Position: Q1 2022 in Review

High Pointe Capital Management reduced its AbbVie (ABBV) stake by 6.8% in Q1 2022, selling an estimated $243K and leaving 22,712 shares worth $3.68M. The position accounts for 2.64% of the portfolio, ranked #3.

High Pointe Capital Management first reported a position in ABBV in Q2 2013 and has held it in 18 quarters since. The position peaked at $4.09M in Q2 2015. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

High Pointe Capital Management held 22,712 shares of AbbVie worth $3.68M as of Q1 2022.
High Pointe Capital Management sold 1,670 AbbVie shares in Q1 2022, an estimated $243K.
AbbVie made up 2.64% of High Pointe Capital Management's portfolio in Q1 2022, its #3 holding.
High Pointe Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 18 quarters since.
High Pointe Capital Management's AbbVie position peaked at $4.09M in Q2 2015.
3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on High Pointe Capital Management's 13F filing for Q1 2022, filed 10 May 2022.